National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Secukinumab (Cosentyx®) for moderate to severe plaque psoriasis

Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Rapid Review

Commenced Completed Outcome
19/12/2014 05/02/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/04/2015 16/09/2015 Reimbursement Not Recommended at submitted price

Secukinumab Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.